---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-063736"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:29:28.324728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galera reports FY2022 net loss $62.2M; avasopasem NDA priority review, PDUFA Aug 9, 2023

## Summary
- Q4 2022 net loss of $16.2M ($0.58 per share); FY2022 net loss $62.2M ($2.30 per share).
- Cash, cash equivalents and short-term investments $31.6M as of Dec 31, 2022; raised $30M in Feb 2023 offering.
- NDA for avasopasem (radiotherapy-induced severe oral mucositis) granted FDA priority review; PDUFA date August 9, 2023.
- No FDA-approved drug currently exists for SOM in head and neck cancer patients; ~43,500 US patients at high risk annually.
- Enrollment ongoing in Phase 2b GRECO-2 (LAPC) and GRECO-1 (NSCLC) trials of rucosopasem; completion expected H2 2023.

## SEC filing metadata
- accession: 0001193125-23-063736
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523063736/0001193125-23-063736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523063736/d300354d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-063736
- JSON: https://secwatch.observer/filing/0001193125-23-063736.json
- Plain text: https://secwatch.observer/filing/0001193125-23-063736.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $(16.2) million, or $(0.58) per share, EPS $(0.58) per share.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $(16.2) million, or $(0.58) per share
  - EPS: $(0.58) per share
  - Result: reported results
  source text: Galera reported a net loss of $(16.2) million, or $(0.58) per share, for the fourth quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523063736/0001193125-23-063736-index.htm
- Earnings Releases
  Galera Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $(62.2) million, or $(2.30) per share, EPS $(2.30) per share.
  - Period: the year ended December 31, 2022
  - Net income: $(62.2) million, or $(2.30) per share
  - EPS: $(2.30) per share
  - Result: reported results
  source text: Galera reported a net loss of $(62.2) million, or $(2.30) per share, for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523063736/0001193125-23-063736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.